CD19-redirected Autologous Cells (CAR-CD19 T Cells)

Phase 1 Unknown 45 enrolled RenJi Hospital CARsgen Therapeutics Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is designed for determining the safety and relative engraftment levels of the redirected autologous T cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell leukemia and malignant lymphoma.

Timeline

Start: 2016-10
Primary completion: 2018-04
Completion: 2020-01

Publications

Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR-CD19 T cells	Cell therapy	1e+07 cells/kg	Intravenous
Subject	CAR-CD19 T cells	Cell therapy	1e+08 cells/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	500 mg/m2	—
Background	Fludarabine	Small molecule	30 mg/m2	—

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

Summary

Timeline

Publications

Drugs

Indications